CRISPR-Cas knockout of miR21 reduces glioma growth

Non-coding RNAs, including microRNAs (miRNAs), support the progression of glioma. miR-21 is a small, non-coding transcript involved in regulating gene expression in multiple cellular pathways, including the regulation of proliferation. High expression of miR-21 has been shown to be a major driver of...

Full description

Bibliographic Details
Main Authors: Nieland, Lisa, Solinge, Thomas S. van, Cheah, Pike See, Morsett, Liza M., Khoury, Joseph El, Rissman, Joseph I., Kleinstiver, Benjamin P., Broekman, Marike L. D., Breakefield, Xandra O., Abels, Erik R.
Format: Article
Published: Cell Press 2022
Online Access:http://psasir.upm.edu.my/id/eprint/100836/
_version_ 1848863427149168640
author Nieland, Lisa
Solinge, Thomas S. van
Cheah, Pike See
Morsett, Liza M.
Khoury, Joseph El
Rissman, Joseph I.
Kleinstiver, Benjamin P.
Broekman, Marike L. D.
Breakefield, Xandra O.
Abels, Erik R.
author_facet Nieland, Lisa
Solinge, Thomas S. van
Cheah, Pike See
Morsett, Liza M.
Khoury, Joseph El
Rissman, Joseph I.
Kleinstiver, Benjamin P.
Broekman, Marike L. D.
Breakefield, Xandra O.
Abels, Erik R.
author_sort Nieland, Lisa
building UPM Institutional Repository
collection Online Access
description Non-coding RNAs, including microRNAs (miRNAs), support the progression of glioma. miR-21 is a small, non-coding transcript involved in regulating gene expression in multiple cellular pathways, including the regulation of proliferation. High expression of miR-21 has been shown to be a major driver of glioma growth. Manipulating the expression of miRNAs is a novel strategy in the development of therapeutics in cancer. In this study we aimed to target miR-21. Using CRISPR genome-editing technology, we disrupted the miR-21 coding sequences in glioma cells. Depletion of this miRNA resulted in the upregulation of many downstream miR-21 target mRNAs involved in proliferation. Phenotypically, CRISPR-edited glioma cells showed reduced migration, invasion, and proliferation in vitro. In immunocompetent mouse models, miR-21 knockout tumors showed reduced growth resulting in an increased overall survival. In summary, we show that by knocking out a key miRNA in glioma, these cells have decreased proliferation capacity both in vitro and in vivo. Overall, we identified miR-21 as a potential target for CRISPR-based therapeutics in glioma.
first_indexed 2025-11-15T13:32:44Z
format Article
id upm-100836
institution Universiti Putra Malaysia
institution_category Local University
last_indexed 2025-11-15T13:32:44Z
publishDate 2022
publisher Cell Press
recordtype eprints
repository_type Digital Repository
spelling upm-1008362023-08-22T03:45:44Z http://psasir.upm.edu.my/id/eprint/100836/ CRISPR-Cas knockout of miR21 reduces glioma growth Nieland, Lisa Solinge, Thomas S. van Cheah, Pike See Morsett, Liza M. Khoury, Joseph El Rissman, Joseph I. Kleinstiver, Benjamin P. Broekman, Marike L. D. Breakefield, Xandra O. Abels, Erik R. Non-coding RNAs, including microRNAs (miRNAs), support the progression of glioma. miR-21 is a small, non-coding transcript involved in regulating gene expression in multiple cellular pathways, including the regulation of proliferation. High expression of miR-21 has been shown to be a major driver of glioma growth. Manipulating the expression of miRNAs is a novel strategy in the development of therapeutics in cancer. In this study we aimed to target miR-21. Using CRISPR genome-editing technology, we disrupted the miR-21 coding sequences in glioma cells. Depletion of this miRNA resulted in the upregulation of many downstream miR-21 target mRNAs involved in proliferation. Phenotypically, CRISPR-edited glioma cells showed reduced migration, invasion, and proliferation in vitro. In immunocompetent mouse models, miR-21 knockout tumors showed reduced growth resulting in an increased overall survival. In summary, we show that by knocking out a key miRNA in glioma, these cells have decreased proliferation capacity both in vitro and in vivo. Overall, we identified miR-21 as a potential target for CRISPR-based therapeutics in glioma. Cell Press 2022-04-06 Article PeerReviewed Nieland, Lisa and Solinge, Thomas S. van and Cheah, Pike See and Morsett, Liza M. and Khoury, Joseph El and Rissman, Joseph I. and Kleinstiver, Benjamin P. and Broekman, Marike L. D. and Breakefield, Xandra O. and Abels, Erik R. (2022) CRISPR-Cas knockout of miR21 reduces glioma growth. Molecular Therapy: Oncolytics, 25. 121 - 136. ISSN 2372-7705 https://www.cell.com/molecular-therapy-family/oncolytics/fulltext/S2372-7705(22)00053-5# 10.1016/j.omto.2022.04.001
spellingShingle Nieland, Lisa
Solinge, Thomas S. van
Cheah, Pike See
Morsett, Liza M.
Khoury, Joseph El
Rissman, Joseph I.
Kleinstiver, Benjamin P.
Broekman, Marike L. D.
Breakefield, Xandra O.
Abels, Erik R.
CRISPR-Cas knockout of miR21 reduces glioma growth
title CRISPR-Cas knockout of miR21 reduces glioma growth
title_full CRISPR-Cas knockout of miR21 reduces glioma growth
title_fullStr CRISPR-Cas knockout of miR21 reduces glioma growth
title_full_unstemmed CRISPR-Cas knockout of miR21 reduces glioma growth
title_short CRISPR-Cas knockout of miR21 reduces glioma growth
title_sort crispr-cas knockout of mir21 reduces glioma growth
url http://psasir.upm.edu.my/id/eprint/100836/
http://psasir.upm.edu.my/id/eprint/100836/
http://psasir.upm.edu.my/id/eprint/100836/